MONTREAL, QUEBEC--(Marketwire - April 16, 2008) - MethylGene Inc. (TSX: MYG), today announced the dosing of the first patient in a Phase I clinical trial of MGCD265 in patients with solid tumor cancers. MGCD265 is an oral, small molecule, multi-targeted kinase inhibitor that targets c-Met, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases. These kinases appear to play key roles in tumor development, tumor survival, and the inappropriate formation of blood vessels (angiogenesis) that nourish the tumor.
